Human umbilical cord mesenchymal stem cells therapy alleviates kidney injury and podocyte apoptosis in Col4a5 knockout male mice

Di Lu; Zhitao Ye; Liujing Xu; Shumin Zhou; Guanyu Li; Jiayi Zhang; Yi Liu; Yue Li; Qizhou Lian; Zheng Shen; Jiao Lin; Qi Wang; Xia Gao

doi:10.1002/ctm2.70506

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (10) : e70506 DOI: 10.1002/ctm2.70506

LETTER TO THE JOURNAL

Human umbilical cord mesenchymal stem cells therapy alleviates kidney injury and podocyte apoptosis in Col4a5 knockout male mice

Author information +

History +

PDF

Cite this article

Download citation ▾

Di Lu, Zhitao Ye, Liujing Xu, Shumin Zhou, Guanyu Li, Jiayi Zhang, Yi Liu, Yue Li, Qizhou Lian, Zheng Shen, Jiao Lin, Qi Wang, Xia Gao. Human umbilical cord mesenchymal stem cells therapy alleviates kidney injury and podocyte apoptosis in Col4a5 knockout male mice. Clinical and Translational Medicine, 2025, 15(10): e70506 DOI:10.1002/ctm2.70506

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Martinez-Pulleiro R, Garcia-Murias M, Fidalgo-Diaz M, Garcia-Gonzalez MA. Molecular basis, diagnostic challenges and therapeutic approaches of Alport syndrome: a primer for clinicians. Int J Mol Sci. 2021; 22(20): 11063.

[2]	Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype‒phenotype correlations in males. J Am Soc Nephrol. 2000; 11(4): 649-657.

[3]	Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009; 27(6): 1421-1432.

[4]	Perico N, Remuzzi G, Griffin MD, et al. Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). J Am Soc Nephrol. 2023; 34(10): 1733-1751.

[5]	Vivarelli M, Colucci M, Algeri M, et al. A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. JCI Insight. 2023; 8(18): e169424.

[6]	Wang W, Zhang M, Ren X, et al. Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury. Mol Ther. 2023; 31(10): 3067-3083.

[7]	Korhonen M, Ylanne J, Laitinen L, Virtanen I. Distribution of beta 1 and beta 3 integrins in human fetal and adult kidney. Lab Invest. 1990; 62(5): 616-625.

[8]	Sachs N, Sonnenberg A. Cell–matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol. 2013; 9(4): 200-210.

[9]	Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023; 8(1): 1.

[10]	Liu L, Yin H, Hao X, et al. Down-regulation of miR-301a-3p reduces burn-induced vascular endothelial apoptosis by potentiating hMSC-secreted IGF-1 and PI3K/Akt/FOXO3a pathway. iScience. 2020; 23(8): 101383.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.